169 results on '"Borer, Jeffrey S"'
Search Results
2. Bioprosthesis Failure
3. Long-Term Durability of Transcatheter Valves
4. Relationship of Body Mass Index With Outcomes After Transcatheter Aortic Valve Replacement: Results From the National Cardiovascular Data–STS/ACC TVT Registry
5. Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial)
6. Application of Transcatheter Repair to Tricuspid Regurgitation
7. Medical misinformation: Vet the message!
8. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
9. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes
10. Role of Payers in the Development of Cardiovascular Therapeutics
11. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial
12. Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al.
13. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis
14. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease
15. Aortic Valve Surgery for Aortic Regurgitation
16. Misconceptions and Facts About Mitral Regurgitation
17. Update on ivabradine for heart failure
18. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial)
19. Repeated Heart Rate Measurement and Cardiovascular Outcomes in Left Ventricular Systolic Dysfunction
20. Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart Failure treatment with the If Inhibitor Ivabradine Trial) Study
21. Cracking the NNT Code: Effect of Ivabradine on Recurrent Hospitalizations
22. Effect of Comorbidities and Risk Factors on Outcomes and Ivabradine’s Effects in Patients With Chronic Systolic Heart Failure in the SHIFT Trial
23. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles
24. Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure
25. Cardiovascular Drug Development
26. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model
27. Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease
28. BETA BLOCKER DOSAGE AND USE OVER TIME IN THE SYSTOLIC HEART FAILURE TREATMENT WITH THE IF INHIBITOR IVABRADINE TRIAL (SHIFT) STUDY
29. How Many Patients Will Benefit From a New Therapy for Chronic Systolic Heart Failure, and What Difference Does it Make? ∗
30. EFFICACY PROFILE OF IVABRADINE IN PATIENTS WITH HEART FAILURE PLUS ANGINA PECTORIS
31. Effect of Ivabradine on Early Readmissions After Hospitalization for Worsening Heart Failure
32. Clinical Evaluation of New Heart Valve Prostheses: Update of Objective Performance Criteria
33. Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates
34. Early Surgery or Watchful Waiting for Asymptomatic Severe Degenerative Mitral Regurgitation
35. Efficacy and Safety of Ivabradine in Patients With Severe Chronic Systolic Heart Failure (from the SHIFT Study)
36. Selective Heart Rate Reduction With Ivabradine Unloads the Left Ventricle in Heart Failure Patients
37. Emerging Clinical Challenges in the Use of Statins
38. Usefulness of Preoperative Exercise Tolerance to Predict Late Survival and Symptom Persistence After Surgery for Chronic Nonischemic Mitral Regurgitation
39. WOMEN HAVE GREATER MID-TERM QUALITY OF LIFE BENEFIT THAN MEN AFTER VALVULAR SURGERY
40. PLASMA TRAIL AND OSTEOPROTEGERIN IN AR, AS AND STABLE CAD: RELATION TO CARDIAC GEOMETRY AND SYMPTOM STATUS
41. BIOMARKERS OF EXTRACELLULAR MATRIX IN LOW FLOW, LOW GRADIENT AORTIC STENOSIS: RELATIONSHIP TO HEMODYNAMIC, FUNCTIONAL, AND CLINICAL OUTCOMES - RESULTS FROM THE MULTICENTER TOPAS (TRULY OR PSEUDO SEVERE AORTIC STENOSIS) STUDY
42. VASODILATING DRUGS PROVIDE NO CLINICAL BENEFIT FOR PATIENTS WITH CHRONIC NONISCHEMIC MITRAL REGURGITATION
43. TRENDS IN RHEUMATIC VALVULAR HEART DISEASE: A LONGITUDINAL STUDY OF HOSPITALIZATIONS AND THE EFFECT OF IMMIGRATION IN NEW YORK CITY (1983-2007)
44. Ivabradine and outcomes in chronic heart failure – Authors' reply
45. Academic perspectives on the United States food and drug administration's guidance for industry on diabetes mellitus
46. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
47. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
48. MYOCARDIAL MRNA CONCENTRATIONS FOR SECRETED BIOMARKERS IN AORTIC REGURGITATION VS AORTIC STENOSIS: CORRELATIONS WITH PLASMA PROTEIN CONCENTRATIONS AND LEFT VENTRICULAR DIMENSIONS
49. PREOPERATIVE EXERCISE CAPACITY BEST PREDICTS SURVIVAL AFTER SURGERY FOR CHRONIC NONISCHEMIC MITRAL REGURGITATION
50. Efficacy of Ivabradine, a Selective If Inhibitor, in Patients With Chronic Stable Angina Pectoris and Diabetes Mellitus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.